FI885329A - Nya fluorcytidinderivat. - Google Patents

Nya fluorcytidinderivat. Download PDF

Info

Publication number
FI885329A
FI885329A FI885329A FI885329A FI885329A FI 885329 A FI885329 A FI 885329A FI 885329 A FI885329 A FI 885329A FI 885329 A FI885329 A FI 885329A FI 885329 A FI885329 A FI 885329A
Authority
FI
Finland
Prior art keywords
fluorcytide
nya
derivatives
nya fluorcytide
fluorcytide derivatives
Prior art date
Application number
FI885329A
Other languages
English (en)
Other versions
FI89804C (fi
FI89804B (fi
FI885329A0 (fi
Inventor
Morio Fujiu
Hideo Ishitsuka
Masanori Miwa
Isao Umeda
Kazuteru Yokose
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI885329A0 publication Critical patent/FI885329A0/fi
Publication of FI885329A publication Critical patent/FI885329A/fi
Application granted granted Critical
Publication of FI89804B publication Critical patent/FI89804B/fi
Publication of FI89804C publication Critical patent/FI89804C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
FI885329A 1987-11-17 1988-11-17 Foerfarande foer framstaellning av terapeutiskt aktiva 5'-deoxi-5-fluorcytidinderivat FI89804C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17
EP87116926 1987-11-17

Publications (4)

Publication Number Publication Date
FI885329A0 FI885329A0 (fi) 1988-11-17
FI885329A true FI885329A (fi) 1989-05-18
FI89804B FI89804B (fi) 1993-08-13
FI89804C FI89804C (fi) 1993-11-25

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885329A FI89804C (fi) 1987-11-17 1988-11-17 Foerfarande foer framstaellning av terapeutiskt aktiva 5'-deoxi-5-fluorcytidinderivat

Country Status (35)

Country Link
US (1) US4966891A (fi)
EP (1) EP0316704B1 (fi)
JP (1) JPH0678350B2 (fi)
KR (1) KR970000241B1 (fi)
CN (1) CN1022688C (fi)
AR (1) AR247217A1 (fi)
AT (1) ATE124951T1 (fi)
AU (1) AU619220B2 (fi)
CA (1) CA1327358C (fi)
CS (1) CS274486B2 (fi)
DE (2) DE10199027I2 (fi)
DK (1) DK170893B1 (fi)
DZ (1) DZ1270A1 (fi)
ES (1) ES2074429T3 (fi)
FI (1) FI89804C (fi)
GR (1) GR3017686T3 (fi)
HK (1) HK1003114A1 (fi)
HU (1) HU199866B (fi)
IE (1) IE883430L (fi)
IL (1) IL88363A0 (fi)
IS (1) IS1895B (fi)
LT (1) LT2185B (fi)
LU (1) LU90769I2 (fi)
LV (1) LV5624A3 (fi)
MC (1) MC1992A1 (fi)
MX (1) MX173347B (fi)
NL (1) NL300045I2 (fi)
NO (2) NO171167C (fi)
NZ (1) NZ226923A (fi)
PH (1) PH25641A (fi)
PT (1) PT89009B (fi)
SU (1) SU1736342A3 (fi)
UA (1) UA19333A (fi)
YU (1) YU47122B (fi)
ZA (1) ZA888428B (fi)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
TW254946B (fi) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003233586A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
CN101128472B (zh) * 2003-12-22 2012-03-14 霍夫曼-拉罗奇有限公司 制备氟胞苷衍生物的方法
ATE426597T1 (de) * 2004-02-18 2009-04-15 Astrazeneca Ab Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
US20080312207A1 (en) * 2004-02-18 2008-12-18 Craig Johnstone Compounds
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
JP2008516935A (ja) 2004-10-16 2008-05-22 アストラゼネカ アクチボラグ フェノキシベンズアミド化合物の製造方法
DK1848414T3 (da) 2005-02-03 2011-07-25 Gen Hospital Corp Fremgangsmåde til behandling af gefitinib-resistent cancer
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
EP1868608A2 (en) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Method for administration of capecitabine
JP2008542247A (ja) * 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての２−フェニル置換イミダゾール［４，５ｂ］ピリジン／ピラジンおよびプリン誘導体
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP2301929A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
ES2384267T3 (es) * 2005-07-21 2012-07-03 Nuvo Research Ag Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
RU2451524C2 (ru) 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
CN101595104A (zh) 2006-12-21 2009-12-02 阿斯利康(瑞典)有限公司 作为glk活化剂的新的晶态化合物
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
US20100130734A1 (en) * 2007-04-20 2010-05-27 Dr. Reddy's Laboratories Ltd. Process for preparing capecitabine
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
KR20120037932A (ko) * 2009-07-23 2012-04-20 시노팜 타이완 리미티드 플루오로시티딘 유도체를 제조하는 방법
WO2011112609A1 (en) 2010-03-12 2011-09-15 Genzyme Corporation Combination therapy for treating breast cancer
EP2833920A2 (en) 2012-04-02 2015-02-11 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
CN104640858B (zh) 2012-09-26 2018-11-06 霍夫曼-拉罗奇有限公司 环醚吡唑-4-基-杂环基-甲酰胺化合物及使用方法
WO2014074725A1 (en) * 2012-11-07 2014-05-15 Ohio State Innovation Foundation Substituted gemcitabine aryl amide analogs
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
CN105792830A (zh) * 2013-03-15 2016-07-20 Z·索 取代的吉西他滨双环酰胺类似物和使用其的治疗方法
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
BR112018076257A2 (pt) * 2016-06-28 2019-03-26 Cellix Bio Private Limited compostos e composições farmacêuticas
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018200859A1 (en) 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
WO2019139921A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
EP3817732A4 (en) * 2018-08-03 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
JP2023523415A (ja) 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
EP4185274A1 (en) 2020-07-24 2023-05-31 Strand Therapeutics Inc. Lipidnanoparticle comprising modified nucleotides
CN116917309A (zh) 2021-01-08 2023-10-20 斯特兰德生物科技公司 表达构建体及其用途
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
DK640388D0 (da) 1988-11-16
DE10199027I2 (de) 2002-01-31
ES2074429T3 (es) 1995-09-16
MX173347B (es) 1994-01-03
DE10199027I1 (de) 2001-08-02
DZ1270A1 (fr) 2004-09-13
JPH01153696A (ja) 1989-06-15
HUT48267A (en) 1989-05-29
IS1895B (is) 2003-10-20
CS747588A2 (en) 1990-09-12
NO171167B (no) 1992-10-26
FI89804C (fi) 1993-11-25
YU209188A (en) 1990-08-31
IL88363A0 (en) 1989-06-30
AU2516888A (en) 1989-05-25
SU1736342A3 (ru) 1992-05-23
DK640388A (da) 1989-05-18
LU90769I2 (fr) 2001-07-02
CN1033183A (zh) 1989-05-31
NO2001013I2 (no) 2006-05-01
EP0316704A3 (en) 1990-11-22
ZA888428B (en) 1989-06-28
NL300045I2 (nl) 2002-01-02
GR3017686T3 (en) 1996-01-31
CS274486B2 (en) 1991-04-11
PT89009A (pt) 1988-12-01
UA19333A (uk) 1997-12-25
HU199866B (en) 1990-03-28
EP0316704A2 (de) 1989-05-24
HK1003114A1 (en) 1998-10-09
CN1022688C (zh) 1993-11-10
IS3412A7 (is) 1989-05-18
PT89009B (pt) 1993-02-26
AR247217A1 (es) 1994-11-30
YU47122B (sh) 1994-12-28
PH25641A (en) 1991-08-21
FI89804B (fi) 1993-08-13
JPH0678350B2 (ja) 1994-10-05
DK170893B1 (da) 1996-03-04
KR890008162A (ko) 1989-07-10
KR970000241B1 (ko) 1997-01-08
MX13836A (es) 1993-10-01
US4966891A (en) 1990-10-30
NL300045I1 (nl) 2001-08-01
NO885106L (no) 1989-05-18
CA1327358C (en) 1994-03-01
DE3854148D1 (de) 1995-08-17
NZ226923A (en) 1990-10-26
FI885329A0 (fi) 1988-11-17
ATE124951T1 (de) 1995-07-15
NO885106D0 (no) 1988-11-16
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
LT2185B (lt) 1993-10-15
AU619220B2 (en) 1992-01-23
EP0316704B1 (de) 1995-07-12
NO171167C (no) 1993-02-03
IE883430L (en) 1989-05-17

Similar Documents

Publication Publication Date Title
FI885329A (fi) Nya fluorcytidinderivat.
FI884914A (fi) Nya insulinderivat.
FI881825A (fi) Framstaellning av nya heterobicykliska kinolonderivat.
FI880173A (fi) Nya peptidasinhibitorer.
FI881650A (fi) Foerfarande foer framstaellning av nya acylderivat.
FI880469A (fi) Nya polyaminderivat.
FI884305A (fi) Nya amidinotricyklderivat.
FI884363A (fi) Nya aluminium-magnesium -hydroxifoereningar.
FI881571A (fi) Nya ribofuransyraderivator.
FI893937A0 (fi) Nya antiarytmiska aemnen ii.
FI881639A (fi) Foerfarande foer framstaellning av nya substituerade anilidderivat.
FI884304A0 (fi) Nya amidinoderivat.
FI882640A0 (fi) Nya heterocykliska pesticida foereningar.
FI881641A (fi) Foerfarande foer framstaellning av nya acylderivat.
FI883146A (fi) Nya foereningar.
FI884106A (fi) Foerfarande foer framstaellning av nya antibakteriella 4-oxo-3-kinolinkarboxylsyror.
FI871320A0 (fi) Nya langmuir-blodgettmembranstrukturer.
FI885063A0 (fi) Nya 4-demetoxi-antracyklinderivat.
FI884901A (fi) Nya rifamycinderivat.
FI884535A (fi) Foerfarande foer framstaellning av nya kinolinium- och isokinoliniumderivat.
FI881921A (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara kinolintioetrar.
FI880144A0 (fi) Nya makromolekyler.
FI873336A0 (fi) Nya makromolekyler.
FI871462A0 (fi) Nya mineralprodukter.
FI870573A0 (fi) Nya etyleniskt omaettade foereningar innehaollande fosfinyl.

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: F. HOFFMANN-LA ROCHE AG

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L186

Extension date: 20130609

MA Patent expired